1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Ipsen
  6. Summary
    IPN   FR0010259150

IPSEN

(IPN)
  Report
Real-time Euronext Paris  -  11:35 2022-07-01 am EDT
92.10 EUR   +2.28%
06/29Ipsen Wins US FDA's Priority Review Tag For Ultra-rare Genetic Disease Drug
MT
06/29Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission
CI
06/28Biopharma Credit Expects Up To $7 Million Loan Prepayment From Epizyme
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
85.55(c) 85.3(c) 89.35(c) 90.05(c) 92.1(c) Last
155 450 110 465 124 313 164 667 97 787 Volume
-2.67% -0.29% +4.75% +0.78% +2.28% Change
More quotes
Estimated financial data (e)
Sales 2022 2 902 M 3 018 M 3 018 M
Net income 2022 736 M 765 M 765 M
Net cash position 2022 576 M 599 M 599 M
P/E ratio 2022 10,6x
Yield 2022 1,28%
Sales 2023 2 972 M 3 091 M 3 091 M
Net income 2023 661 M 687 M 687 M
Net cash position 2023 1 173 M 1 220 M 1 220 M
P/E ratio 2023 11,5x
Yield 2023 1,29%
Capitalization 7 594 M 7 899 M 7 899 M
EV / Sales 2022 2,42x
EV / Sales 2023 2,16x
Nbr of Employees 5 744
Free-Float 41,8%
More Financials
Company
Ipsen specializes in the research, development, manufacturing and marketing of medications. Sales break down by family of products as follows: - specialty drugs (92.1%). Sales break down by therapeutic area between oncology (81.4%), neuroscience (1516.7 and rare diseases (1.9%); - consumer healthcare products (7.9%): products used in the treatment of gastrointestinal disorders, neurodegenerative pathologies and... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Ratings of Ipsen
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about IPSEN
06/29Ipsen Wins US FDA's Priority Review Tag For Ultra-rare Genetic Disease Drug
MT
06/29Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patie..
CI
06/28Biopharma Credit Expects Up To $7 Million Loan Prepayment From Epizyme
MT
06/27SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Monday
MT
06/27Wall Street Set for Positive Open, Extending Gains on Easing Inflation Expectations
MT
06/27Top Premarket Gainers
MT
06/27TRANSCRIPT : Epizyme, Inc., Ipsen S.A. - M&A Call
CI
06/27European shares hit two-week high as China eases COVID-19 curbs
RE
06/27Epizyme Agrees to be Acquired by Ipsen for $247 Million
MT
06/27France's Ipsen Launches Tender Offer to Purchase US Biopharmaceutical Epizyme
MT
06/24IPSEN : Security operations
CO
06/09Ipsen receives positive opinion in Europe for Dysport in the management of urinary inco..
AQ
06/09Ipsen Granted Positive Opinion in EU For Urinary Incontinence Management Injection Dysp..
MT
06/09IPSEN : Rediffusion AG – 24 mai 2022 (2)
PU
06/03IPSEN : 2022 SM – Voting results
PU
More news
News in other languages on IPSEN
06/29Paris anxieuse
06/29ACTUALIZACIÓN DE LAS FUERTES VARIACI : las esperanzas de Just Eat se disparan, las de Cary..
06/29POINT SUR LES FORTES VARIATIONS DU J : les espoirs de Just Eat s'envolent, contrairement à..
06/29CAC40 : la prudence domine avant des statistiques majeures
06/29Paris repart à la baisse, inquiète de l'activité économique
More news
Analyst Recommendations on IPSEN
More recommendations
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 92,10 €
Average target price 102,50 €
Spread / Average Target 11,3%
EPS Revisions
Managers and Directors
David G. Loew Chief Executive Officer & Director
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Marc M. P. de Garidel Non-Executive Chairman
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
IPSEN14.41%7 899
JOHNSON & JOHNSON3.76%472 389
PFIZER, INC.-11.21%293 506
ELI LILLY AND COMPANY17.38%292 291
ROCHE HOLDING AG-15.48%272 104
ABBVIE INC.13.59%271 782